Kasamon YL, Wahl RL, et al: Biol Blood Marrow Transplant; FDG-PET shows promise for adjusting chemotherapy protocols based upon early imaging results in patients with newly diagnosed aggressive NHL.
Discussion: Before the automated serum screening chemistry panel that began in the early 1970s, the disorder had been symptomatic with kidney stones, skeletal disease, and/or neuromuscular dysfunction. Currently, primary hyperparathyroidism (PHPT) frequently has fewer signs or symptoms. Without symptoms it became doubtful whether parathyroid surgery was appropriate. A conference held at the National Institutes of Health in 1990 issued guidelines to surgical and nonsurgical management. Prospective studies yielding greater insight into pathogenesis and natural disease course led to a second international workshop on the management of asymptomatic primary hyperparathyroidism at the NIH in 2002. This conference revised the guidelines for diagnosis as well as for surgical versus nonoperative medical management. At both conferences, parathyroid surgery was cited as the only definitive therapy, even for those not meeting guidelines for surgery. These guidelines were intended exclusively for asymptomatic PHPT; those with complications of PHPT--kidney stones, fractures, overt neuromuscular disease, or symptoms of hypercalcemia, warrant parathyroid surgery. The Third International Workshop on Primary Hyperparathyroidism was held in May 2008. At that conference, preoperative diagnostic imaging was a major topic. The main goal of preoperative imaging in PHPT is to assist anatomic localization of abnormal functioning or enlarged parathyroid glands. Its purpose is not to establish a diagnosis of PHPT, nor do negative imaging studies rule out the diagnosis. Since all imaging studies have at best moderately good predictive values, preoperative parathyroid imaging studies should be done only in those with an established biochemical diagnosis of PHPT. The appropriate choice of imaging studies depends on the surgical plan: unilateral versus bilateral, and whether the procedure will be a second exploration in a consequently scarred operative field. The most frequently ordered imaging studies are sestamibi scintigraphy and cervical ultrasound. The reported sensitivity of scintigraphy varies widely between institutions, and sonography is operator dependent. CT and MRI are occasionally used, notably in cases of persistent or recurrent hyperparathyroidism. For those undergoing a repeat neck exploration, PTH assay of the aspirate from an FNA of a suspected adenoma can clinch the diagnosis preoperatively. In particularly difficult cases, angiography and selective venous sampling for PTH can be used when noninvasive studies are equivocal or conflicting.
Reviewer's Comments:
The group of symposium articles on primary hyperparathyroidism in the February 2009 issue of J Clin Endocrinol Metab should be of interest to our subscribers. Nuclear Medicine plays a primary role in the diagnosis and management of hyperparathyroidism, and not just because sestamibi scintigraphy is recognized as the primary preoperative imaging method. Because many of us work closely with our endocrinology colleagues on thyroid problems, they feel comfortable discussing and referring their parathyroid cases. Because many nuclear physicians perform bone densitometry, we are involved in monitoring as well. The heart rate response to both adenosine and regadenoson stress is blunted in patients with diabetes mellitus.
Background:
The vasodilatory agents adenosine and regadenoson are frequently used in combination with myocardial perfusion imaging. A good heart rate response to the infusion of these agents suggests that the patient was properly prepared (eg, no recent caffeine) and that adequate vasodilation was achieved. However, it has been previously shown that the heart rate response in diabetics is blunted compared to those without diabetes.
Objective: To determine whether heart rate response will be lower in patients with than in those without diabetes mellitus.
Methods: 2000 patients were evaluated who underwent pharmacologic vasodilatory stress testing in combination with myocardial perfusion imaging. The heart rate response was compared between diabetics and non-diabetics.
Results:
There were 643 patients with diabetes compared to 1357 without. The percent increase in the heart rate over baseline, defined here as the heart rate response, was 29% in diabetics versus 36% in non-diabetics. This was found to be due to the higher baseline heart rate in diabetics (68) as compared to non-diabetics (65; P <0.001). The average peak heart rate was 88 in both diabetics and non-diabetics.
Conclusions:
The heart rate response to adenosine and regadenoson stress testing is blunted in patients with diabetes. This finding is due to the fact that the average baseline heart rate in diabetics (68) was higher than in non-diabetics (65), although the peak heart rate was the same.
Reviewer's Comments:
This study is misleading in that it gives variation in terms of the standard error of the mean instead of the preferred standard deviation. Only by having such a high number of patients could they possibly have found a statistically significant difference. The standard deviation equals the standard error times the square root of the sample size. Using standard deviations, the authors' results show that the average baseline heart rate was 68 +/-12 in diabetics compared to 65 +/-11 in non-diabetics. This large degree of overlap means that the statistically significant findings (which use the standard error for computation) cannot be applied to individual patients (where the standard deviation is used). Prophylactic neck lymph node dissection for small tumors initially staged node negative modifies the use of radioiodine ablation in 30% of patients.
Background:
In lower risk papillary thyroid cancer (PTC) patients, the role of I-131 remnant ablation is controversial. Even though the prognostic value of lymph node (LN) status in papillary thyroid cancer has not been clearly demonstrated, current practice regards the existence of locoregional LN metastasis as meriting more aggressive treatment and active monitoring. Specifically, a recent consensus statement published by the American Thyroid Association recommends the use of I-131 ablation following removal of PTC primaries <1 cm in size only in those with locoregional lymph node metastases. No definite position was taken on node-negative patients with primaries between 1 and 2 cm in size. The authors of this paper thought the uncertainty might be reduced by more precise determination of lymph node status.
Objective:
To assess the value of prophylactic neck dissection of lymph node compartments in patients with small (<2 cm) primary papillary thyroid cancers.
Methods:
The study group included 115 patients with PTC <2 cm in size and without LN metastases demonstrated at neck ultrasound. All patients underwent total thyroidectomy, and central and ipsilateral LN dissection.
Results: LN metastases were found in 42.0% of patients (n=48) with both central and lateral LN dissection; only 36.7% of patients (n=42) would have been discovered if prophylactic LN dissection had been limited to the central neck. In multivariate analysis, age <50 years (P =0.0007) and existence of a tumor extension beyond the thyroid capsule (P =0.048) were predictive of LN involvement. LN status modified the decision for postsurgical radioiodine ablation for 25 of 115 patients (21.7%). Among the 67 patients treated with I-131 on total body scan, 8 patients had foci in the neck outside the thyroid bed. One patient had diffuse uptake in the lungs. A second radioiodine treatment was administered 6 months later to these 8patients. One patient (0.9%) presented with a postoperative laryngeal palsy, and another patient (0.9%) presented with hyperparathyroidism requiring calcium and vitamin D supplementation. At 1 year, no patient showed suspicious cervical LN on ultrasound. Tg levels were undetectable in 1 patient.
Conclusions:
Prophylactic neck dissection for small tumors initially staged node negative modifies the use of radioiodine ablation in 30% of patients.
Reviewer's Comments: These results certainly make a cogent case for more extensive lymph node dissection so as to tailor I-131 treatment. In fact, there may be the value added curative removal of metastatic lymph nodes. The practical question is whether patients in this very low-risk category will be eager, or even willing, to undergo more extensive surgery for a very low-risk tumor. The American Thyroid Association recommends I-131 remnant ablation in all cases with cervical lymph node metastases.
Discussion:
The vast majority of papillary thyroid cancer (PTC) patients achieve a normal lifespan following total thyroidectomy and I-131 ablation. But many patients experience cervical lymph node recurrence, and >5% die of disease. A major question in reducing locoregional recurrence is whether surgery or radioiodine--or neither or both--in patients with microcarcinomas is the optimal approach. Close to 90% of PTCs are small, ie, <2 cm and half are 1 cm. The smaller the primary, the better the prognosis, but recurrence rates need to be lowered because 10-year cancer-specific mortality rates are significant even for tumors <1 cm in size. Recent studies have found increased risk for death in follicular thyroid cancer if there are lymph node metastases, and that lymph node metastases remaining after initial therapy are the most common cause of subsequent recurrence. Postoperative I-131 ablation therapy of normal residual thyroid tissue can eliminate occult residual lymph node metastases and facilitate follow-up with serum Tg measurements. A 2008 report found a 2% lower risk of distant metastatic recurrences with remnant ablation.The American Thyroid Association recommends I-131 remnant ablation in all cases with cervical lymph node metastases. The problem with routine remnant ablation is the immediate risk for radiation injury to salivary glands, oral tissues, lacrimal ducts, and long-term risk of radioiodine-induced non-thyroidal second cancers. Cumulative I-131 doses >500 mCi increase the risk of leukemia, but it is not known whether a single 100 mCi increases cancer risk. It has been documented that I-131 residence times were significantly shorter in the prepared thyrogen compared with patients who underwent withdrawal, thus reducing radiation to normal tissues. Some reports have found that 30 mCi achieves successful ablation as effectively as much larger doses. A main issue in the initial treatment of small PTCs is the difficulty in accurately identifying lymph node metastases preoperatively by ultrasonography. Even at surgery, direct visualization cannot reliably detect lymph node metastases. Prophylactically dissecting the central and ipsilateral lymph node compartments is the most reliable method of detecting lymph node metastases. Prophylactic dissection to determine tumor involvement would result in an appropriate radioiodine therapy for those with lymph node metastases while avoiding this treatment for those free of residual locoregional tumor.
Reviewer's Comments:
The use of I-131 ablation in lower risk thyroid cancer is, if you will excuse the expression, a "hot" topic. I found this editorial informative, clinically valuable, and reader friendly. Although it focuses on surgical issues, the editorial provides the latest suggestions on I-131 remnant ablation. What I learned from this paper is that we would be wise to consider the details of the preablation work-up--surgical, sonographic, and histologic--in order to tailor the I-131 ablative dose. A positive ECG response to adenosine stress is most likely a false-positive in patients with normal myocardial perfusion on SPECT imaging and no history of previous myocardial infarction or revascularization.
Background: Adenosine stress testing performed in conjunction with myocardial perfusion imaging is frequently used in the detection of coronary artery disease and risk stratification. While most patients with ST segment depression on electrocardiography have reversible perfusion defects, it is not well-known what the prognosis is for patients with a positive adenosine stress ECG and a negative myocardial perfusion scan.
Objective: To show on long-term follow-up that these patients continue to be at low risk. Methods: A positive ECG response to adenosine stress was defined as 1 mm ST segment depression. Patients with a positive adenosine stress ECG test, a normal myocardial perfusion scan, and a past medical history negative for myocardial infarction or previous coronary revascularization were evaluated. Outcome measures tracked were total mortality, cardiac mortality, nonfatal myocardial infarction, and coronary revascularization.
Results: 73 patients were followed-up for 5 years for mortality. Four of 5 patients were female. During the follow-up period, there were 10 deaths, of which 5 were determined to be noncardiac. For the other end points, follow-up was complete for 21 months. During this time period, no patient had a myocardial infarction and 7 underwent coronary revascularization. The annual rate of myocardial infarction during the follow-up period was 0% in the study sample and the rate of revascularization was 5.5%.
Conclusions:
In patients with a past medical history negative for previous myocardial infarction or coronary revascularization, an abnormal adenosine stress ECG response most likely represents a false-positive for inducible ischemia when the myocardial perfusion scan is normal.
Reviewer's Comments: Note that the results of this study only apply to those with a past medical history negative for prior myocardial infarction or revascularization. The authors did not state the risk factors (eg, diabetes) that were present at the time of myocardial perfusion imaging in the patients that died during the follow-up period. Improvements from the resolution recovery software may be used to reduce acquisition times or administered activity.
Background: New reconstruction techniques have been introduced that compensate for spatial resolution in SPECT imaging, potentially allowing the reduction of acquisition time while maintaining imaging quality.
Objective: To evaluate gated myocardial perfusion SPECT acquired with a 50% reduction in imaging time and processed with the GE Evolution for Cardiac software.
Methods:
The Evolution software compensates for collimator scatter and penetration along with the distance dependent system resolution. This software requires a look-up table of the point spread data for the collimators with which it is used. A total of 212 subjects participated in this investigation. Overall, 112 patients had rest and stress gated MPS studies acquired for the normal acquisition time (approximately 12 minutes) with repeated MPS studies acquired for 6 minutes; 56 of those had the short study first while the other 56 had the full-time study first. The remaining 100 had repeat full-time acquisitions. Studies were performed on the Infinia Hawkeye SPECT/CT system with CT transmission imaging for attenuation correction. All studies were reconstructed both with and without attenuation correction. Studies were read by 2 nuclear medicine physicians. Comparisons were made of final diagnosis, transient ischemic dilation (TID), ventricular volumes and ejection fraction, and summed stress (SSS), rest (SRS), and difference (SDS) scores. Diagnostic agreement between the different groups was assessed with the intra-class correlation coefficient and the kappa -coefficient, while linear regressions and Bland-Altman analysis was performed on the quantitative parameters.
Results:
The full-time acquisition test-retest had excellent concordance with an intraclass correlation coefficient (ICCr) of 0.98 for the quantitative parameters (LVEF, SSS, SRS, SDS, TID). The concordance of the half-time with the full-time acquisitions was only slightly worse with an ICCr of 0.95 for the studies corrected for attenuation correction and an ICCr = 0.94 for the uncorrected studies. The image quality of the half-and full-time studies was essentially the same and the clinical diagnosis determined from the half-time images agreed with the full-time diagnosis in 95% of cases.
Conclusions:
The results from the half-time studies were largely in agreement with the full-time study results. The authors note that agreement was only slightly lower than the full-time test-retest results.
Reviewer's Comments:
This investigation included the crucial step of performing test-retest studies with the full-time acquisition so that the repeatability of the procedure was monitored. The authors provide convincing evidence that similar results can be obtained when the Evolution software is applied to the half-time acquisitions. Reducing the acquisition time may reduce motion artifacts and be better tolerated by patients. 
MPI Plays Pivotal Role in Risk Stratification in CAD Patients

Current Advances in Vasodilator Pharmacological Stress Perfusion Imaging.
Druz RS: Semin Nucl Med; 39 (May): [204] [205] [206] [207] [208] [209] Regadenoson may be used instead of adenosine or dipyridamole for stress MPI.
Background: Myocardial perfusion imaging (MPI) using pharmacologic coronary vasodilators is a long established component of care for managing many patients with known or suspected coronary artery disease (CAD). Adenosine and dipyridamole both are potent simulators of epicardial artery dilatation. Recently a newer agent, regadenoson, which is a more selective coronary vasodilator, has moved into clinical practice.
Objective: To provide the reader with a review and update of these drugs and their application in stress MPI. Discussion: Adenosine and dipyridamole are generally regarded as nonspecific cardiac adenosine receptor agonists. The authors note that regadenoson is highly specific to the cardiac receptor for adenosine. Consequently, there is likely to be less pulmonary bronchospasm associated with using regadenoson. Interestingly, less flushing is reported with the use of regadenoson, yet more patients report headaches as a side effect with adenosine. The incidence of AV block appears to be reduced with regadenoson compared to adenosine. In contrast to adenosine and dipyridamole, regadenoson is given as a single IV bolus with peak action at 2 to 4 minutes. Studies directly comparing adenosine and regadenoson demonstrate essentially the same degree of accuracy for detecting CAD for each agent. The authors also review results from the INSPIRE and the COURAGE Imaging sub-study. Findings from these large trials emphasized the importance of MPI with vasodilator stress for risk stratification of patients with CAD.
Conclusions:
The authors conclude: "Vasodilator stress perfusion imaging is safe and effective in identifying significant coronary artery disease. Newer agents allow better tolerance, ease of administration, and improved side-effect profile. Recent trials have firmly established a pivotal role of vasodilator stress perfusion imaging in risk stratification and therapeutic guidance of patients with stable coronary artery disease."
Reviewer's Comments:
The authors failed to mention the specific literature pertaining to successful use of regadenoson in patients with asthma. However, I am not aware of specific studies yet using regadenoson in patients with COPD, although we have done so at our facility without problems. I would be remiss if I did not inform the readership that, in our experience with this agent, there is a small but not insignificant fraction of patients who defecate following administration of regadenoson. We have reduced this to almost zero by performing "slow" IV injection. Overall, we've found that patients generally tolerate this drug better than adenosine. Finally, the use of regadenoson with Rb-82 may be limited by the relatively short duration of action of this drug. SPECT systems that are optimized for a specific imaging task can provide substantial improvements over conventional gamma -camera based approaches.
Background: Myocardial perfusion imaging typically requires an acquisition time of >12 minutes for each SPECT study. New SPECT instrumentation has become commercially available that substantially reduces the acquisition time.
Objective: To evaluate the Spectrum Dynamics D-SPECT system for myocardial SPECT imaging. Methods: The D-SPECT represents a new approach to SPECT imaging. It consists of 9 independently rotating collimated cadmium zinc telluride (CZT) cameras arranged in an L-shape mounted inside a stationary gantry. Each individual camera can rotate independently to collect projection data. High-efficiency tungsten collimators are used along with a resolution recovery algorithm to maintain spatial resolution with high count sensitivity. Measurements of spatial resolution and sensitivity in the D-SPECT were made with line sources and were compared with those obtained from a conventional SPECT system. Energy resolution was also evaluated and multi-energy anthropomorphic heart phantom studies were acquired for both systems. Comparisons were also made on 18 Tc-99m sestamibi stress and rest studies between the D-SPECT and conventional SPECT systems. The D-SPECT studies were acquired 30 minutes after the conventional studies and were acquired for 2 minutes versus the 11-minute acquisition for the conventional study.
Results:
The spatial resolution (FWHM) was 3.9 mm for the D-SPECT and 10 mm for the conventional system, but no resolution recovery was performed for the conventional measurement. The count sensitivity for the D-SPECT was more than a factor of 10 higher than the conventional system. The energy resolution was 5.7% facilitating the dual isotope studies. Clinical image quality was ranked slightly higher for the D-SPECT. The diagnostic results were similar and the summed stress scores and summed rest scores for the groups had a correlation near 0.8.
Conclusions:
The improved imaging characteristics of the D-SPECT will make it appealing for myocardial perfusion imaging. The authors also note that this design is likely to have additional molecular imaging applications.
Reviewer's Comments:
The D-SPECT shows how new approaches designed for a specific task can provide significant improvement over conventional approaches. The use of CZT enables this development because its compactness allows sampling modes that are not possible with scintillators. Other new SPECT imaging systems using clever sampling schemes are also being introduced at this time. In a recent issue of the Journal of Nuclear Medicine , Drs. Hay, McDougall, and Sisson said they would eliminate diagnostic whole-body radioiodine scintigraphy prior to ablation. They also question the use of routine I-131 remnant ablation in all patients with well-differentiated thyroid carcinoma (WDTC) because the majority of patients must endure the effect of radiation while only a small minority will benefit. Rather than ablate remnant tissue, they would prefer I-123 SPECT/CT or I-124 PET/CT to differentiate remnants from lymph nodes for better specificity and I-124 to increase sensitivity. Dr. Bourgeois does not agree that therapeutic I-131 should be given without preceding imaging. Pretherapeutic scintigraphy identifies locoregional or distant iodine-avid metastases. Also, pretherapeutic imaging allows calculation of the lowest dose for ablation-considerably less in most cases than the 100 mci usually given. In Europe, higher doses still require hospitalization. Furthermore, scintigraphic imaging as part of postsurgical management is useful both to determine the necessity for ablation and to exclude unexpected metastases. Regarding the value of I-131 ablation, it needs to be considered if antibodies are present; if so, ablation is needed to destroy the normal thyroid tissue to eliminate a source of antigenic stimulation. There is an additional goal of ablation: namely, elimination of microfoci of carcinoma, which is an important prognostic factor. Kuffner et al recently found regional lymph node metastases in 10% of papillary primaries 1 cm, so that 10% of those aged >45 years but with small lesions will be undertreated in the Hay et al recommendation. Furthermore, Hay et al do not consider histologic criteria in determining candidates for ablation. It is appropriate to distinguish follicular from papillary carcinoma. Follicular has a worse prognosis than papillary carcinoma, and it is inappropriate to lump them together. Dr. Bourgeois believes that patients with stage 1 disease be imaged before determining the necessity for ablation.
Reviewer's Comments: I am pleased to see such a well-presented response to the editorial of Drs. Hay, McDougall, and Sisson that seriously challenges the current widespread practice standard (including ours) of routinely ablating most patients with differentiated thyroid carcinoma. I believe that pretreatment scanning is valuable to exclude those with no functioning remnant from ablation. As for side effects of ablation, I am considering a lower dose than the 100 mci we have been using-in the range of 50 to 75 mci-based on some recent reports of the effectiveness of ablative doses at that level. 
Can FDG PET Predict Response to Chemoradiation in Esophageal Cancer?
Mean and Maximum Standardized Uptake Values in [18F] FDG-PET for Assessment of Histopathological Response in
Oesophageal Squamous Cell Carcinoma or Adenocarcinoma After Radiochemotherapy. Schmidt M, Bollschweiler E, et al: Eur J Nucl Med Mol Imaging; In this study, there was large overlap between the SUVavg/max between responders and nonresponders to chemoradiation in patients with esophageal cancer. Thus, FDG PET was not an adequate predictor of neoadjuvant treatment response.
Objective: To evaluate FDG PET in predicting the response to neoadjuvant chemoradiation in esophageal cancer. Background: Esophageal cancer has one of the poorest 5-year survival rates, estimated at 15% to 40% despite recent advances in staging and surgical techniques. The development of neoadjuvant chemotherapy and radiation therapy has been developed in an attempt to further bolster the treatment armamentarium. Although FDG PET has been shown to be a valuable tool in the staging and detection of the recurrence of esophageal cancer, its use as a predictor of response to neoadjuvant chemoradiation is not yet clear. Further evaluation of this potential use of FDG PET is important because patients who are poor responders can be spared a multi-modality regimen that may not offer any change in overall survival.
Methods: 55 patients (34 with adenocarcinoma, 21 with squamous cell) with a biopsy-proven esophageal cancer were evaluated. Each patient had baseline FDG PET imaging as well as PET scans 3 months following a standardized neoadjuvant chemoradiation of cisplatin, 5 FU, and 36 Gy of radiation. Regions of interest to measure SUVavg and SUVmax were drawn on both baseline and post-therapy scans, with statistical analyses performed to determine if there were differences in SUVs between responders and nonresponders. All surgical specimens were histologically assessed for treatment response.
Results:
Histopathologically, 21 patients were responders and 34 were nonresponders, with those with squamous cell cancer demonstrating a 50% response rate compared to only 29% among patients with adenocarcinoma. There was large overlap in the SUV values (both avg and max) in responders and nonresponders among both the squamous cell and adenocarcinoma subgroups. Also noted was that baseline SUVs in adenocarcinoma patients were higher in nonresponders than in responders, in contrast to the squamous cell patients. Reviewer's Comments: This study is of clinical interest as the authors point out that their results are in discordance with others that have shown that FDG PET is valuable in distinguishing neoadjuvant responders from nonresponders among patients with esophageal cancer. These discrepant findings could be explained by differences in study methods such as timing of the post-therapy scan, use of the more objective semi-quantitative versus subjective SUV measurements of response, and the treatment regimen used. The authors also propose the hypothesis of "cellular stunning." Defined as the down-regulation of glucose transporters, this stunning phenomenon could lead to under-detection of viable tumor tissue on post-therapy scans. Performing a liquid gastric emptying study prior to a solid one provides added value in diagnosing gastroparesis.
Conclusions
Objective: To establish normal values for liquid gastric emptying, and to determine whether liquid gastric emptying studies have added value to solid studies in the diagnosis of gastroparesis.
Participants/Methods: This study included 101 patients (77 female, 24 male; age range, 17 to 77 years) with symptoms of gastroparesis. Seven of these patients had diabetes. Thirty patients were healthy volunteers. All patients underwent both solid and liquid gastric emptying studies that were performed on the same day in the morning. Medications that might interfere with the studies were discontinued, and the patients could ingest nothing by mouth from the night before the studies. Each patient was administered 0.2 mCi (7.4 MBq) of In-111-DTPA in 300 mL of water orally with imaging for 30 minutes (1 minute per frame). This was followed by a standardized solid meal consisting of an egg-substitute sandwich with 2 mCi (74 MBq) of Tc-99m-sulfur colloid. Images for the solid study were acquired immediately (0 hours), and then at 1, 2, 3, and 4 hours after ingestion. Regions of interest were placed around the stomach with generation of time-activity curves. For liquids, a best-fit exponential emptying rate (T1/2) was determined. For solids, percentage emptying at 4 hours was calculated. In addition, the downscatter from the In-111 liquid into the Tc-99m solid meal was determined.
Results:
In the healthy patients, an exponential gastric emptying pattern was noted. The normal upper range of T1/2 for liquids in these patients was 19 to 22 minutes. Delayed solid gastric emptying was seen in 16% of patients. Delayed liquid emptying was noted in 36%. Thirty-two percent of patients with normal solid emptying had delayed liquid emptying. There was no significant In-111 downscatter into the Tc-99m window.
Conclusions:
The authors found added value of performing a liquid gastric emptying study in addition to a solid one for the detection of gastroparesis.
Reviewer's Comments: Based on the findings from this study, one would assume that performing a liquid gastric emptying first would be preferable. If that study were abnormal (which is quicker and easier to perform), then a subsequent solid gastric emptying study would not be necessary. SPECT imaging should be part of the procedure for assessment of stress injury to the femoral neck when performing a bone scan.
Background: Femoral neck stress fractures may occur in long distance runners, military personnel, or others involved in intense exercise routines. Bone scanning is known to have very good sensitivity and specificity for detecting stress fractures in general. The early detection of femoral neck stress fracture can prevent progression to a full-thickness fracture that may have devastating consequences.
Objective: To assess the utility of SPECT imaging compared to standard planar bone imaging for detecting stress fractures involving the femoral neck.
Design/Methods: This was a retrospective study of physically active patients who underwent bone imaging with Tc-99m MDP for suspected stress fracture. A total of 38 patients underwent planar bone imaging followed by MRI of the hips; another group of 33 patients underwent planar imaging plus SPECT imaging prior to MRI of the hips. All patients were military trainees. Stress fracture grade was determined based on the degree of edema seen on MRI as either low or high grade.
Results:
In the first group, planar imaging had a sensitivity of 50% (6 of 12). In the second group, SPECT imaging had a sensitivity of 92% (12 of 13). Specificity was similar for the 2 methods. SPECT imaging was reported to be better for determining high-grade fractures as defined by MRI.
Conclusions: "The addition of SPECT to planar imaging should be considered in a young active population with hip pain."
Reviewer's Comments: I was a bit puzzled by the way the authors chose to do their data analysis. In addition, the authors did not say what their guidelines were for SPECT, or planar, imaging in distinguishing high-versus low-grade fractures. Nevertheless, I think the message is reasonably clear. SPECT imaging should be part of the procedure for assessment of stress injury to the femoral neck when a bone scan is performed.
Additional Keywords: Stress Fractures print tag: () Refer to original journal article.
